仲夏时节，成都产业园区发展热潮涌动——低空经济交流服务中心的投运，为产业链企业筑起落地发展新支点；高端医械"研造一体"基地的正式签约入 驻，加速国产微创器械破局进程；分布式光伏并网发电，则迈出成都未来科技城绿色转型的关键一步。 三大项目在仲夏时节同步突破，不仅刷新了成都园区建设的"进度条"，更以低空、生物医药、绿色能源的协同跃升，为成都新质生产力发展注入强劲动 能。 助力低空"高飞" 成都未来科技城低空经济交流服务中心投运 同时，服务中心内设置有"园区企业服务驿站"，面向所有入驻成都未来科技城的企业开放。驿站将配备2位工作人员驻点，提供工商财税、报规报建、法 律金融等事项的咨询服务和代办帮办。 ▲成都未来科技城低空经济交流服务中心投运 低空经济是成都未来科技城的主导产业。去年以来，成都未来科技城先后落地沃飞长空总部基地、凌空天行全国总部及高超音速飞行器研发生产基地等一 批龙头项目。同时，一座低空经济专业化科技园区——"未来翼谷"已然呈现。建筑面积59万平方米，按照"科技信息融合、产业人群融合、生产要素融 合、功能业态融合"思路，打造国内一流的eVTOL和无人机科技创新、先进制造高地。低空经济交流服务中心的启用 ...

卢毅浙江省人民医院肝胆胰外科副主任医师 商报记者曾润玥通讯员杨陶玉马梦迪 随后卢毅团队为患者实施了腹腔镜胰十二指肠切除术，凭借着每年超百例的微创技术积累，卢毅成功将 手术时间从最初的8小时缩短至4.5个小时，并且患者术后第二天即可下床，10天顺利出院。如今五年过 去，王女士复查显示持续无瘤生存，"原本以为生命只剩半年时间，现在却能每天接送孙女上学，是转 化化疗给了我第二次生命。" 数据显示，转化化疗通过术前缩小原发肿瘤、消灭远处转移，可使部分晚期胰腺癌患者获得手术切除的 根治机会，5年生存率较传统治疗显著提高。 从"一刀切"到"量体裁衣" 转化治疗重构晚期肿瘤患者治疗新模式 无独有偶，67岁的李阿姨(化名)2年前因腹部胀痛就诊时，被确诊为胆囊癌伴肝脏及后腹膜淋巴结转 移，彻底失去了手术根治机会。"传统单纯化疗对晚期胆囊癌效果有限，患者平均生存不足半年。"为 此，卢毅团队创新采用了化疗联合PD-1抑制剂的转化治疗方案，4个周期化疗后影像学检查显示：后腹 膜淋巴结基本消失，肝脏转移灶缩小超60%，成功为机器人辅助微创胆囊癌根治术创造了条件。 "患者胆囊结石病史长达10年，结石长期对胆囊进行摩擦和刺激是癌变主因。" ...

麦迪科技 2025 年第一次临时股东大会会议材料 苏州麦迪斯顿医疗科技股份有限公司 会议资料 二〇二五年六月三十日 麦迪科技 2025 年第一次临时股东大会会议材料 苏州麦迪斯顿医疗科技股份有限公司 议案 1：关于公司 2024 年度未弥补亏损达到实收股本总额三分之一的议案 ........ 6 麦迪科技 2025 年第一次临时股东大会会议材料 苏州麦迪斯顿医疗科技股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》 《中华人民共和国证券法》、中 国证监会《上市公司股东大会规则》以及《公司章程》《股东大会议事规则》的 相关规定，特制定 2025 年第一次临时股东大会会议须知。 六、本次会议采用现场投票与网络投票相结合的方式逐项进行表决。股东以 其持有的有表决权的股份数额行使表决权，每一股份享有一票表决权。股东在投 票表决时，应在表决票中每项议案下设的"同意"、 "反对"、 "弃权"三项中任选 一项，并以打"√"表示，多选或不选均视为无效票，作弃权处理。 麦迪科技 2025 年第一次临时股东大会会议材料 七、为保证每位参会股东的权益，谢绝 ...

Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., is planning to expand its business scope to include the research and development of intelligent robots, manufacturing and sales of service consumer robots, and sales of intelligent unmanned aerial vehicles, in order to accelerate its innovative business development [1][2]. Group 1: Business Scope Changes - The company intends to add the following activities to its business scope: research and development of intelligent robots, manufacturing of service consumer robots, sales of service consumer robots, and sales of intelligent unmanned aerial vehicles [1]. - The previous business scope included the research and development of medical devices, computer software and hardware, medical robot navigation systems, minimally invasive surgical platform systems, and mechatronic products, among others [1]. - The updated business scope will still encompass the original activities while incorporating the new areas of focus [1]. Group 2: Company Charter Revision - The company will revise its Articles of Association to reflect the changes in its business scope [1]. - Other provisions in the Articles of Association will remain unchanged [1]. - The proposed changes will require approval from the shareholders' meeting and must be registered with the market supervision administration [2].

Core Viewpoint - Sichuan Bank is focusing on technological innovation and optimizing credit policies to support various sectors, including artificial intelligence and high-end equipment, thereby injecting financial momentum into the development of new productivity in Sichuan [1][4]. Group 1: Financial Support for Innovation - Sichuan Bank is directing credit resources towards the livelihood sector, significantly supporting small and micro enterprises that benefit the public through technological innovation [2]. - The bank provided a tailored financial service plan for Chengdu Bornsi Medical Robotics Company, offering a 10 million yuan two-year unsecured loan to assist in the development of a minimally invasive surgical robot, which is priced at one-third of similar imported devices [2]. - Sichuan Bank also supported Sichuan Digital World Cultural Technology Company with a 10 million yuan loan within a week to meet its financing needs, promoting the development of the domestic gaming industry [2]. Group 2: Consumer Demand Stimulus - In early 2023, Sichuan Bank launched twelve measures to "expand domestic demand and promote consumption," planning to issue over 100 billion yuan in loans to key consumption areas such as housing, automobiles, and tourism [3]. Group 3: Support for Sci-Tech Enterprises - Sichuan Bank has been addressing the financing difficulties faced by sci-tech enterprises by increasing the supply of small and micro loans and innovating financial products [4]. - The bank provided a comprehensive financial service plan for Chengdu Guoxing Aerospace Technology Company, utilizing supply chain finance to optimize cash flow management and reduce financing costs [4]. - Sichuan Bank partnered with China Minmetals Financial Leasing Company to offer one-stop financial services to leading companies in the low-altitude travel sector, facilitating their international business expansion [4]. Group 4: Enhancing Financial Service Capabilities - Sichuan Bank is strengthening its top-level design and mechanism construction to create a comprehensive financial service system, including the establishment of a technology finance center and specialized branches [5]. - The bank has developed specific credit management measures for technology finance to improve the efficiency of business operations [5]. - In March 2023, Sichuan Bank was the first state-owned bank in the region to implement a flexible financial service model for technology enterprise mergers and acquisitions [6].

Core Insights - The Chinese government is promoting the integration of artificial intelligence (AI) in healthcare, emphasizing the application of AI in various medical fields to enhance efficiency and service delivery [1][5]. Group 1: AI in Diagnostic Services - AI tools like the "DeepSeek" model are being utilized in hospitals to improve diagnostic efficiency, allowing doctors to analyze complex cases more quickly and accurately [2][3]. - Over 100 hospitals across more than 20 provinces in China have implemented the DeepSeek model, enhancing the overall management and operational efficiency of healthcare institutions [5]. Group 2: AI in Pediatric Healthcare - The "福棠·百川" pediatric AI model integrates the expertise of over 300 pediatric specialists and extensive clinical guidelines, improving diagnostic accuracy for common and rare pediatric diseases [4]. - The model supports personalized analysis and dynamic tracking of the latest research, aiming to reduce misdiagnosis and over-treatment risks [4]. Group 3: AI in Medical Devices - AI and augmented reality (AR) technologies are being applied in minimally invasive surgeries, such as lung nodule removal, significantly improving precision and reducing patient discomfort [6][7]. - Advanced imaging devices, like the intelligent CT scanner, utilize AI to optimize scanning processes and enhance diagnostic accuracy, particularly in primary healthcare settings [8]. Group 4: AI in Drug Development - AI is accelerating the drug development process, exemplified by a treatment for idiopathic pulmonary fibrosis that has shown promising clinical results, with AI reducing development time by two-thirds [10][11]. - The integration of AI tools throughout the drug development lifecycle is enhancing efficiency and reducing costs, with numerous AI-driven drug candidates currently in clinical trials [12]. Group 5: Future of AI in Healthcare - AI is viewed as a supportive tool for healthcare professionals, enhancing their capabilities rather than replacing them, allowing for more focus on complex medical tasks [13][14].

Core Insights - The integration of AI in healthcare is transforming the industry, with significant advancements showcased at the 91st China International Medical Equipment Fair (CMEF) [2][4][10] - The Chinese government is actively supporting the innovation and development of medical devices through policy reforms and financial incentives, including a special bond of 148 billion yuan [2][15] - Domestic companies are making strides in high-end medical equipment, with products that enhance precision and accessibility in healthcare [10][15][22] Group 1: AI and Medical Technology - The AI-driven medical models, such as Mindray's "Qiyuan" critical care model, can integrate patient data and provide treatment suggestions within five seconds, already implemented in several top-tier hospitals [4][10] - Haier Biomedical has launched an AI strategy with its "Kuidou" sample library model, focusing on intelligent management of biological samples [4][6] - The emergence of AI-powered solutions in blood sugar management, remote emergency care, and imaging diagnostics is pushing the medical field from "assistance" to "autonomy" [4][10] Group 2: Innovations in Medical Devices - The introduction of the "Newton 3D" intraoperative CT and surgical robot by GeRui Technology showcases advancements in precision surgery, offering real-time 3D imaging and navigation for complex procedures [13] - The ZAP-X radiation surgery robot, featuring a unique self-shielding design, is aimed at improving the safety and precision of radiation therapy for brain and head-neck tumors [15] - The launch of innovative non-invasive respiratory devices, such as the SyncFree algorithm-based respiratory machine by Yuyue Medical, highlights the shift towards home healthcare solutions [20] Group 3: Market Trends and Consumer Needs - The demand for home healthcare solutions is rising, particularly for chronic conditions like COPD and OSA, with projections indicating significant increases in patient numbers by 2025 [16][18] - The domestic hearing aid market is experiencing a transformation, with local products now competing with foreign brands due to advancements in technology and affordability [20] - The overall vitality of the domestic medical device industry is evident, as it continues to evolve towards high-quality development and innovation [22]

预计2024年净亏损不超过2.75亿美元（约合19.9亿元人民币）， 较上年同期亏损收窄超过 58% 。亏损的显 著收窄主要归因于资源聚焦和成本优化措施，使得经营费用占收入比率同比下降约28个百分点。 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月9日，微创医疗（00853.HK）发布了2024年度业绩预告。 # 财务数据 收入增长 尽管面临快速变化的外部环境和行业政策影响，微创医疗预计2024年收入同比增长近10%，剔除汇率影响 后， 收入预计达到 74.07亿 元人民币 。 净亏损收窄 合作伙伴征集：2025全球手术机器人大会 海外业务增长 通过全球化平台的协同效应， 微创医疗出海业务收入同比增长约 80% ，进一步推动了整体收入增长。 产品注册与创新 报告期内，集团及联营公司共有6款产品进入国家创新医疗器械审批程序（绿色通道）， 累计达到36款，连 续十年在同行业中排名第一 。此外，集团及联营公司共获得46项国家药品监督管理局颁发的三类医疗器械首 次注册证，并在43个海外市场获得184项首次注册证，其中包括1 ...

前言 = 华创研究 关于免费声明全文,详见本PPT最后部分 第一部分 屈光手术是什么? 01 ■ 过去十年屈光技术迭代速度放缓，随着成熟术式和材料的生命周期走向中后期，屈光项目客单价和盈利能力出现一定波动。然而，随着以新 一代技术为代表的优质供给不断涌现，屈光手术市场正迎来新一轮变革，有望激发巨大的潜在需求释放 ■ 新技术引领屈光手术市场新变革。承载着人们对美好生活的希望，新技术的诞生总是振奋人心。随着以精准全飞秒4.0、全光塑以及 EVO+ICL代表的新术式全面推广，以及未来蔡司新一代机器人全飞秒VISUMAX 800及新微创手术SMILE pro与ICL新材料的上市推广，我 们预计新术式将显著拉动屈光市场客单价上行 ■非刚需人群的潜在需求亟待释放。国内屈光手术市场空间广阔，2022年市场规模接近350亿元。然而从渗透率来看，2021年我国每千人近 视手术量仅为0.7，远低于同期发达国家的水平（如美国每千人2.6）。通过进一步用户画像分析，国内手术需求以刚需为主，而发达国家则 以改善性需求为主；对比之下，国内在非刚需人群、女性以及中低度近视市场的渗透率仍有巨大的提升空间 ■ 屈光手术作为民营眼科医疗服务中的 ...